Q-omics provides the consensus-scored ELOCP4 profile across patient tissues and cancer cell-line models. ELOCP4 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, ELOCP4 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, ELOCP4 RNA expression shows 2,446 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, KIRC, and STAD as cancer lineages where ELOCP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP4 survival associations across molecular data types. ELOCP4 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP4 RNA expression–survival associations across cancer types. High ELOCP4 expression shows unfavorable associations in COAD, SKCM, LGG and KIRP, but favorable associations in ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for ELOCP4 RNA expression.
This table summarizes ELOCP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP4 shows lower tumor expression in KIRC. The KIRC box plot shows higher ELOCP4 RNA expression in normal versus tumor tissue (log2 FC = −0.102, t-test p = .027).
This table shows molecular features associated with ELOCP4 in patient tissues and cancer cell lines. In patient samples, ELOCP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
